Australia markets open in 5 hours 52 minutes

Athira Pharma, Inc. (ATHA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
10.71+1.08 (+11.21%)
At close: 4:00PM EDT
10.81 +0.10 (+0.93%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close9.63
Bid10.67 x 1800
Ask10.82 x 800
Day's range10.21 - 11.54
52-week range8.88 - 34.79
Avg. volume351,820
Market cap399.439M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-1.45
Earnings date10 Nov 2021 - 15 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est39.50
  • GlobeNewswire

    (ATHA) Alert: Did You Acquire Athira Before November 2020? Should Management be Held Accountable for Investors Losses? Contact Johnson Fistel

    SAN DIEGO, Oct. 23, 2021 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP is investigating potential claims on behalf of Athira Pharma, Inc. ("Athira" or the "Company") (NASDAQ: ATHA) against certain of its officers and directors. Recently a class action lawsuit was filed in federal court against the Company on behalf of purchasers of the securities of Athira from September 18, 2020 and June 17, 2021 (the "Class Period"). The Athira Pharma class-action lawsuit alleges that, throughout the Class Period, d

  • Motley Fool

    Why Shares of Athira Pharma Are Climbing Today

    What happened Shares of biopharmaceutical company Athira Pharma (NASDAQ: ATHA) are up close to 13% as of 11:19 a.m. EDT on Friday after the company announced it had finished enrolling participants in its ACT-AD clinical trial for ATH-1017, a therapy for mild to moderate Alzheimer's disease.

  • GlobeNewswire

    Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease

    -Topline data targeted for 1H22- BOTHELL, Wash., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, announced today that it has completed enrollment in ACT-AD, a Phase 2 randomized, placebo-controlled study of ATH-1017 in patients with mild-to-moderate Alzheimer’s disease. ATH-1017 is a small molecule designed to enhance the activity of H